Pharsight

1. Drug name - LORBRENA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111	PFIZER	Macrocyclic derivatives for the treatment of diseases	Mar, 2033 (10 years from now)
US10420749	PFIZER	Crystalline form of lorlatinib free base	Jul, 2036 (13 years from now)
CN104169286A	PFIZER	Macrocyclic Derivative For Treating Proliferative Diseases	Feb, 2033 (10 years from now)
CN104169286B	PFIZER	Macrocyclic Derivative For Treating Proliferative Diseases	Feb, 2033 (10 years from now)
IN201407205P4	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
IN298989B	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP2822953B9	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP2822953B1	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP2822953A1	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP3328867B9	PFIZER	Crystalline Form Of Lorlatinib Free Base	Jul, 2036 (13 years from now)
EP3328867A1	PFIZER	Crystalline Form Of Lorlatinib Free Base	Jul, 2036 (13 years from now)
EP3328867B1	PFIZER	Crystalline Form Of Lorlatinib Free Base	Jul, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376	PFIZER	Crystalline form of lorlatinib free base	Jul, 2036 (13 years from now)

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
25MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.